169 related articles for article (PubMed ID: 33050940)
41. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Brand M; Muller A; Alsop J; van Schaik IN; Bembi B; Hughes D
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
[TBL] [Abstract][Full Text] [Related]
42. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.
Schwartz IVD; Göker-Alpan Ö; Kishnani PS; Zimran A; Renault L; Panahloo Z; Deegan P;
Mol Genet Metab Rep; 2018 Mar; 14():73-79. PubMed ID: 29326879
[TBL] [Abstract][Full Text] [Related]
43. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074
[TBL] [Abstract][Full Text] [Related]
44. Activated and Memory T Lymphocytes in Children with Gaucher Disease.
Zahran AM; Eltayeb AA; Elsayh KI; Saad K; Ahmad FA; Ibrahim AIM
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):263-269. PubMed ID: 27638481
[TBL] [Abstract][Full Text] [Related]
45. In vitro osteoclastogenesis from Gaucher patients' cells correlates with bone mineral density but not with Chitotriosidase.
Bondar C; Mucci J; Crivaro A; Ormazabal M; Ceci R; Oliveri B; González D; Rozenfeld P
Bone; 2017 Oct; 103():262-269. PubMed ID: 28736246
[TBL] [Abstract][Full Text] [Related]
46. The impact of Gaucher disease and its treatment on quality of life.
Hayes RP; Grinzaid KA; Duffey EB; Elsas LJ
Qual Life Res; 1998 Aug; 7(6):521-34. PubMed ID: 9737142
[TBL] [Abstract][Full Text] [Related]
47. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
48. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
Benedik-Dolničar M; Kitanovski L
Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
[TBL] [Abstract][Full Text] [Related]
49. Life expectancy in Gaucher disease type 1.
Weinreb NJ; Deegan P; Kacena KA; Mistry P; Pastores GM; Velentgas P; vom Dahl S
Am J Hematol; 2008 Dec; 83(12):896-900. PubMed ID: 18980271
[TBL] [Abstract][Full Text] [Related]
50. Pleural tuberculosis in a patient with untreated type 1 Gaucher disease.
Dulgar O; Eskazan AE; Ersen E; Demiroz AS; Turna A; Oz B; Tuzuner N
J Infect Chemother; 2016 Jan; 22(1):53-7. PubMed ID: 26459658
[TBL] [Abstract][Full Text] [Related]
51. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
52. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.
Bennett LL; Turcotte K
Drug Des Devel Ther; 2015; 9():4639-47. PubMed ID: 26345314
[TBL] [Abstract][Full Text] [Related]
53. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
54. Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.
Gras-Colomer E; Martínez-Gómez MA; Moya-Gil A; Fernandez-Zarzoso M; Merino-Sanjuan M; Climente-Martí M
Clin Pharmacokinet; 2016 Sep; 55(9):1103-13. PubMed ID: 27083470
[TBL] [Abstract][Full Text] [Related]
55. Validation of the Airway-Dyspnoea-Voice-Swallow (ADVS) scale and Patient-Reported Outcome Measure (PROM) as disease-specific instruments in paediatric laryngotracheal stenosis.
Nouraei SA; Makmur E; Dias A; Butler CR; Nandi R; Elliott MJ; Hewitt R
Clin Otolaryngol; 2017 Apr; 42(2):283-294. PubMed ID: 27542317
[TBL] [Abstract][Full Text] [Related]
56. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy.
Weinreb NJ; Barbouth DS; Lee RE
Blood Cells Mol Dis; 2018 Feb; 68():211-217. PubMed ID: 27816427
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
58. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients.
Tantawy AAG; Adly AAM; Abdeen MSED; Salah NY
Neurogenetics; 2020 Jul; 21(3):159-167. PubMed ID: 32215803
[TBL] [Abstract][Full Text] [Related]
59. Controlled attenuation parameter and liver stiffness measurements using transient elastography by FibroScan in Gaucher disease.
Lipiński P; Szymańska-Rożek P; Socha P; Tylki-Szymańska A
Mol Genet Metab; 2020 Feb; 129(2):125-131. PubMed ID: 31704237
[TBL] [Abstract][Full Text] [Related]
60. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
